Edesa Biotech, Inc. has entered into an At The Market Offering Agreement to sell up to $3.87 million of its common shares through H.C. Wainwright & Co., LLC, while terminating a previous agreement with Canaccord Genuity LLC, under which it raised approximately $2 million.